South Korean university specialising in natural-material scaffolds and tissue engineering for bone, cartilage, and wound repair with clinical translation focus.
Chonbuk National University (since renamed Jeonbuk National University) is a South Korean research university whose entire H2020 footprint sits in regenerative medicine and tissue engineering. Their researchers develop scaffolds from natural biomaterials designed to repair bone, cartilage, and wounds, combining materials science with biomedical application. They engage with European research networks as third-party contributors in MSCA staff exchange programmes, sending and receiving researchers rather than holding direct project budgets. Their work traces an arc from laboratory-level scaffold development toward clinically-oriented product translation, with a growing emphasis on sustainable, green chemistry-based manufacturing.
Both REMIX and SHIFT centre on scaffold-based tissue engineering, with REMIX establishing natural material scaffolds and SHIFT extending the work to bone and cartilage-specific constructs.
SHIFT (2021-2026) explicitly targets bone and cartilage tissue engineering with a bench-to-bedside translation focus.
Natural materials appeared as a core theme in REMIX and wound healing became an explicit output target in SHIFT, forming a consistent thread across both projects.
Green chemistry appears as a keyword only in SHIFT (2021-2026), signalling a newer research direction toward sustainable biomaterial production.
In vitro testing was a defined component of REMIX, providing preclinical assessment of scaffold material performance.
In their first H2020 project (REMIX, 2017), CBNU's focus was foundational: developing scaffolds from natural materials and validating them through in vitro testing — building the basic research infrastructure for regenerative medicine. By SHIFT (2021), the emphasis had shifted clearly toward applied outcomes: product design, green chemistry, and specific clinical targets including bone, cartilage, and wound healing, with explicit bench-to-bedside language entering the vocabulary. The trajectory moves from material methodology toward clinically-relevant, sustainably produced tissue products.
CBNU is moving from foundational scaffold research toward application-driven tissue engineering products with a sustainability dimension, making them a relevant partner for projects targeting clinical translation or green biomedical manufacturing.
CBNU participates exclusively as a third party in MSCA-RISE staff exchange projects, meaning they contribute researchers and expertise rather than holding formal partnership status or project budgets — a standard arrangement for non-EU universities in MSCA schemes. This limits their financial stake but positions them as knowledge-exchange nodes, contributing specialist skills without project management overhead. With 7 unique partners across 7 countries from only 2 projects, they operate within moderately-sized but internationally diverse consortia.
CBNU has connected with 7 unique partners across 7 countries through 2 MSCA-RISE projects, reflecting the broad geographic spread typical of staff exchange schemes. Their network is internationally diverse but limited in depth, given the small project count.
As a South Korean university engaged in European MSCA research exchanges, CBNU brings an Asia-Pacific research perspective into European tissue engineering consortia — a relatively uncommon combination. Their presence in both foundational scaffold science (REMIX) and clinically-oriented product development (SHIFT) makes them a versatile partner for groups wanting to connect basic biomaterials research with downstream translation. The adoption of green chemistry in their most recent project suggests alignment with sustainable biomedical manufacturing, a direction growing in EU funding priorities.
